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A bidirectional crosstalk between peripheral players of immunity and the central nervous
system (CNS) exists. Hence, blood–brain barrier (BBB) breakdown is emerging as a
participant mechanism of dysregulated peripheral–CNS interplay, promoting diseases.
Here, we examine the implication of BBB damage in neurodegeneration, linking it
to peripheral brain-directed autoantibodies and gut–brain axis mechanisms. As BBB
breakdown is a factor contributing to, or even anticipating, neuronal dysfunction(s), we
here identify contemporary pharmacological strategies that could be exploited to repair
the BBB in disease conditions. Developing neurovascular, add on, therapeutic strategies
may lead to a more efficacious pre-clinical to clinical transition with the goal of curbing
the progression of neurodegeneration.
Keywords: blood–brain barrier, neurodegeneration, peripheral immunity, traumatic brain injury, status epilepticus,
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BRAIN BARRIERS’ PATHS, LEAKS, AND
NEURODEGENERATION
The term neurodegenerative describes a progressive deterioration of the central nervous system
(CNS) that is frequently associated with abnormal accumulation of proteins. Importantly,
neurofibrillary tau-protein tangles are not only a major sign of Alzheimer’s disease (AD) but
are reported in temporal lobe epilepsy and post-traumatic encephalopathies (Tai et al., 2016).
Among the emerging disease mechanisms, a peripheral–CNS pathological interplay is proposed
to contribute to the neurodegenerative process (Marchi et al., 2014; Engelhardt et al., 2017; Fung
et al., 2017; Pavlov and Tracey, 2017; Prinz and Priller, 2017; Le Page et al., 2018). Accordingly,
harmful events occurring at the cerebrovascular interface are being examined as key determinants
partaking to or even preceding neurodegeneration (Zlokovic, 2011; Nation et al., 2019; Sweeney
et al., 2019). At the cerebrovasculature, specialized endothelial cells, mural cells, and astroglia
constructs (Abbott et al., 2010; Giannoni et al., 2018; Sweeney et al., 2019) provide physical and
biological properties governing the homeostatic–immune interactions between peripheral blood
cells, or molecules, and brain neuroglia. The physiological parenchymal milieu composition ensures
a healthy neuronal transmission, attainable because of the tightness of the blood–brain barrier
(BBB; Zlokovic, 2008; Giannoni et al., 2018; Nation et al., 2019). At the pial arterial and venous level,
the cerebrovasculature is permissive to blood cells or molecules, while it becomes impermeable at
the arteriole–capillary level where barriers’ properties are fully established (Abbott et al., 2010).
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BBB vessels also contribute to cerebrospinal and interstitial fluid
movements and the elimination of waste products from the
interstitial and perivascular spaces (Noé and Marchi, 2019).
It is increasingly recognized that a BBB pathological
imprint can provoke a brain pro-inflammatory disequilibrium
sufficient to modify neuronal activity in the long term
(Marchi et al., 2007, 2014; Nation et al., 2019). Vascular-
dependent mechanisms of neurodegeneration can rapidly elicit
as a consequence of peripheral infections, head trauma,
ischemic stroke, or status epilepticus (Figure 1; Nation et al.,
2019; Sweeney et al., 2019). These are risk factors for the
development of long-term neurodegenerative sequelae and
encephalopathies (e.g., post-concussion or head trauma-related
chronic traumatic encephalopathy, CTE), cerebral amyloid
angiopathy (CAA), AD, and epilepsy. Under conditions of
increased BBB permeability, an aberrant bidirectional exchange
between the neurovascular unit and the peripheral blood occurs,
compounding to neurodegenerative modifications (Figure 1;
Marchi et al., 2014; Engelhardt et al., 2017; Fung et al., 2017;
Pavlov and Tracey, 2017; Prinz and Priller, 2017; Le Page et al.,
2018). Completing a vicious cycle, beta-amyloid deposition in the
brain can provoke capillaries dysfunction (Thomas et al., 1996;
Zhang et al., 1997; Iadecola et al., 1999; Deane et al., 2003, 2012;
Nortley et al., 2019). As an example, reactive oxygen species and
endothelin-1 production were proposed to elicit vasoconstriction
at pericyte locations (Nortley et al., 2019). A question remains





The communication between the peripheral blood and the brain
occurs at preferential cerebrovascular sites (Zlokovic, 2011; Noé
and Marchi, 2019), e.g., at post-capillary venules or pial vessels,
and by a system of lymphatic vessels draining the cerebrospinal
and interstitial fluids to cervical lymph nodes (Aspelund et al.,
2015; Louveau et al., 2015a,b, 2018). At the intravascular level,
moving leukocytes shape a peripheral–brain immune dialog
where endothelium activation or permeability, perivascular
immune cell homing, and brain entry of immune soluble factors
prompt and sustain neuroglia inflammation [Figure 1; see
Engelhardt et al. (2017) and Ransohoff (2016) for fundamental
aspects of endothelial–leukocyte adhesion]. The implication of
the cerebrovascular interface to innate and adaptive modalities of
immunity is central (Schwartz and Shechter, 2010; Sommer et al.,
2017). Adaptive immunity to the brain requires T- and B-cell
stimulation at extra-CNS lymphatic organs and by professional
antigen-presenting cells (Janeway et al., 2001), thus implying the
existence of a peripheral–brain immune dialog, e.g., via the CNS
vascular and lymphatic routes (Noé and Marchi, 2019).
A question exists on whether neurodegeneration may result
from autoimmune-like processes (Table 1). Contingent to a
prolonged or recurrent BBB permeability, specific antigens could
exit the brain to reach the bloodstream, mounting a peripheral
humoral response. Newly formed brain-directed autoantibodies
could be neuropathological upon their entry into the brain across
a continuously damaged BBB (Levin et al., 2010). Importantly,
autoantibodies and autoreactive T cells were reported in the
cerebrospinal fluid (CSF), sera, as well as in the brain of AD
patients and experimental models of disease (Table 1; Kronimus
et al., 2016; Wu and Li, 2016). Anti-Aβ antibodies (Ig type
G) correlated with scores of dementia (Wilson et al., 2009).
Intrathecal antibodies against tau filaments were reported in
AD patients (Mruthinti et al., 2004) and were proposed as
contributors of disease progression (Bartos et al., 2012). Anti-
tau autoantibodies are not specific to AD as they are increased
in patients suffering from other neurodegenerative diseases, e.g.,
multiple sclerosis (Fialová et al., 2011).
The significance of peripheral autoantibodies as biomarkers
of neurodegenerative conditions also remains to be established.
Autoantibodies against the glutamate receptor N-methyl-D-
aspartate receptor (NMDAR) were detected in plasma of AD
patients (Davydova et al., 2007). Levels of antibodies were
shown to correlate with clinical severity, as patients affected by
moderate and severe dementia presented a twofold autoantibody
increase compared with patients suffering from mild dementia
(Davydova et al., 2007). The presence of autoantibodies against
5-HT was also reported (Myagkova et al., 2001), with levels
increasing during the mild phase of the disease, subsequently
reaching a plateau (Myagkova et al., 2001). Similar findings
were reported for autoantibodies directed against the receptor
for advanced glycation end products (Wilson et al., 2009).
In a transgenic model of AD, autoantibodies against the
sphingolipid ceramide correlated with amyloid plaque increase
(Posse de Chaves and Sipione, 2010; Dinkins et al., 2015).
Autoantibodies against ATP synthase (Vacirca et al., 2012), α(1)-
adrenergic, and the β(2)-adrenergic receptors were also reported
(Karczewski et al., 2012). Autoantibodies against the α(1)-
adrenergic and the β(2)-adrenergic receptors may contribute to
vascular lesions and increased plaque formation in AD patients
(Karczewski et al., 2012).
Importantly, not all autoantibodies are harmful. Brain-
reactive natural autoantibodies (NAbs) are protective (Britschgi
et al., 2009; Kellner et al., 2009; Dodel et al., 2011; Bach and Dodel,
2012). NAbs are mostly IgM and are spontaneously produced.
NAbs are polyreactive with low affinity for self-antigens
(Casali and Schettino, 1996). Physiologically, NAbs facilitate
phagocytosis of apoptotic cells, inhibit inflammatory pathways,
and have a role in maintaining immune tolerance (Elkon and
Silverman, 2012). NAbs to Aβ can inhibit plaque aggregation,
block Aβ toxicity, and catalyze Aβ clearance (Lindhagen-Persson
et al., 2010). Immunotherapies using specific, or aspecific,
autoantibodies were tested. Bapineuzumab is the humanized
form of a monoclonal anti-Aβ antibody targeting the N-terminus
of Aβ. In phase II trials, Bapineuzumab administration reduced
Aβ plaques in AD brains (Salloway et al., 2009; Rinne et al.,
2010) and was associated with decreased total and phospho-
tau levels in the CSF (Asuni et al., 2007). Bapineuzumab
was, however, discontinued after a phase III trial and showed
no beneficial effects on cognitive or functional outcomes
(U.S. National Library of Medicine, 2019a,b). Aducanumab
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FIGURE 1 | The periphery–brain interplay and CNS disease: the neurovascular pathological imprint. (A) Proper peripheral–brain segregation under healthy conditions
(neurovascular unit, NVU; blue lines). (B) Pathological insult(s) elicited in the periphery or in the brain (traumatic brain injury, TBI; status epilepticus, SE) converge to
NVU damage (e.g., BBB permeability) and neuro-inflammation, leading to temporary or prolonged loss of brain homeostatic control (B1, red arrows). (B2) Under
conditions of BBB permeability, concentration gradients favor brain-derived proteins to extravasate into the peripheral blood. Under this condition, a peripheral
auto-immune reaction may mount leading to the production of autoantibodies, possibly re-entering into the CNS if BBB damage endures (B3).
(BIIB037) is a human monoclonal antibody selectively targeting
aggregated Aβ (oligomers and fibrils) (Sevigny et al., 2016).
An Aducanumab phase III trial was terminated as endpoints
were not meet. The analysis of a larger data set is ongoing.
Tau immunotherapies are also being developed, attenuating or
preventing functional impairment in experimental models, as
reviewed in Sigurdsson (2018).
AUTOANTIBODIES AND
POST-TRAUMATIC ENCEPHALOPATHY
Resulting from repeated head trauma and BBB damage, chronic
traumatic encephalopathy (CTE) presents with accumulation of
neurofibrillary tau-protein tangles. In TBI subjects, blood and
CSF autoantibodies were suggested as etiological components
or as possible biomarkers of neurodegeneration (Raad et al.,
2014; Kobeissy, 2015; Table 1). Anti-glial fibrillary acidic protein
(GFAP) fragments were found in the sera of TBI patients (Zhang
et al., 2014). Serum autoantibodies against S100B were reported
in American football players when repeated sub-concussive
events were associated with BBB damage (Marchi et al.,
2013). Autoantibodies against the neuronal α7-subunit of the
acetylcholine receptor (Sorokina et al., 2011) as well as AMPA and
NMDA receptors (Goryunova et al., 2007) were detected in TBI
subjects, while IgG autoantibodies to neurons and basal lamina
were reported in rat serum following experimental head trauma
(Rudehill et al., 2006). Autoantibodies to the pituitary gland were
reported in TBI subjects 3 years after the trauma (Tanriverdi
et al., 2008, 2010). Damage to the pituitary gland is distinctive
of the TBI pathology with 20–50% of patients showing some
degrees of pituitary dysfunction, which affects growth hormone
production (Aimaretti et al., 2005; Tanriverdi et al., 2006). An
association between anti-pituitary autoantibodies and pituitary
dysfunction was reported in patients suffering from mild TBI,
including repetitive concussions (Tanriverdi et al., 2010).
Autoreactive antibodies have been proposed for the treatment
of TBI sequelae. The presence of hyper-phosphorylated tau
accumulating in neurofibrillary tangles is a characteristic of CTE
(Omalu et al., 2010). Even if phospho-tau is detectable only at
low levels acutely after TBI (Smith et al., 2003; Blennow et al.,
2012; Goldstein et al., 2012; Mannix et al., 2013), a specific form
of phospho-tau can be produced in response to TBI (cis P-tau)
(Kondo et al., 2015). This protein spreads throughout the brain,
harming cells and leading to post-traumatic neurodegeneration
and dementia. In two animal models of TBI, administration of
a monoclonal antibody discriminating between the cis and the
trans forms of the protein and blocking cis P-tau prevented the
onset of tauopathy and cortical atrophy. These accumulating
evidence supports the possible involvement of autoantibodies in
post-TBI neurodegenerative conditions, perhaps providing new
disease biomarkers and therapeutic entry points.
THE GUT–BRAIN AXIS AND
NEURODEGENERATION: IS THERE A
BARRIER IMPLICATION?
Here, we discuss a specific framework where alterations of the
gut microbiota (GM) could impact BBB permeability, promote
neuro-inflammation, and favor neurodegenerative modifications
(Figure 2; Braniste et al., 2014; Cerovic et al., 2019; Parker
et al., 2019; Wang et al., 2019). Bacteria, viruses, parasites, and
non-pathogenic fungi constitute the intestinal microbiota. These
complex communities of microbes colonizing the gastrointestinal
tract are major players in health. Modern life and diets have
progressively induced changes in the composition of the GM,
perhaps for the worse, as this can contribute to chronic illnesses
(Lozupone et al., 2012; Myles, 2014; Kumar and Forster, 2017;
Shanahan et al., 2017; Cryan et al., 2019; Pagliai et al., 2019;
Reza et al., 2019). Intestinal microbes can influence brain
function through a continuous dialog involving the immune,
Frontiers in Aging Neuroscience | www.frontiersin.org 3 February 2020 | Volume 12 | Article 3
fnagi-12-00003 February 3, 2020 Time: 16:6 # 4
Giannoni et al. Neurodegeneration and Blood–Brain Interfaces
FIGURE 2 | Gut–brain axis: communication routes and physiological barriers.
A double, peripheral, and brain homeostatic control is performed by the
intestinal–epithelial and blood–brain barriers under healthy conditions. Rupture
of one barrier (e.g., gut) may impact the other (e.g., brain), with the blood
stream and the immune system being the facilitators or the arbitrators of the
pathological spread and neuro-inflammation.
the vascular, and the nervous systems (Figure 2; Schroeder
and Bäckhed, 2016; Cox and Weiner, 2018; Butler et al.,
2019; Cryan et al., 2019). Modifications in the composition
of the GM was reported in brain disorders, such as autism
(Adams et al., 2011; Kang et al., 2019), depression (Kelly et al.,
2016; Zheng et al., 2016), Parkinson’s disease (Scheperjans
et al., 2015; Sampson et al., 2016), and AD (Cattaneo et al.,
2017; Vogt et al., 2017; Zhuang et al., 2018). Intriguingly, the
extent of the amyloid pathology in AD mice appears to be
dependent of the microbial status, which is specific to the
animal housing facility. APP/PS1 mice bred in a germ-free
facility displays decreased amyloid plaque number compared
to mice housed in non-germ-free conditions (Harach et al.,
2017). Moreover, the administration of broad-spectrum,
combinatorial antibiotics to APP/PS1 mice, either during the
peri-natal or the adult stage, reduced brain Aβ deposition
(Minter et al., 2016, 2017).
Existing reports support the hypothesis of a possible infectious
origin of AD. Aβ was proposed as an antimicrobial peptide
(Soscia et al., 2010; Moir et al., 2018) responding to pathogens
(Kumar et al., 2016; Eimer et al., 2018). Infectious agents, such
as Chlamydia pneumonia, Proprionibacterium acne, Helicobacter
pylori, Porphyromonas gingivalis, or spirochetes, are associated
with AD (Kornhuber, 1996; Balin et al., 1998; Kountouras et al.,
2006; Miklossy, 2011; Poole et al., 2015). A microbial hypothesis
is supported by evidence describing the presence of viruses, such
as Herpes simplex virus type I, in the brains of AD patients (Lin
et al., 2002; Alonso et al., 2014; Itzhaki et al., 2016).
Within the complex interplay between the gut microbiome
and the CNS, a role for brain barriers and neuroinflammation is
becoming important (Braniste et al., 2014; Cerovic et al., 2019;
Parker et al., 2019; Wang et al., 2019). The impact of the gut
microbiome composition on CNS health was reported (Amedei
and Boem, 2018; Chu et al., 2019; Sherwin et al., 2019; Virtue
et al., 2019). Recent work demonstrated that GM composition
controls BBB development and permeability in mice (Braniste
et al., 2014). In AD, increased gut permeability due to GM
dysbiosis was reported during prolonged stress. In this condition,
molecules that are normally secluded in the intestine, e.g.,
inflammatory mediators, bacteria, or bacterial-derived agents,
could leak out and reach the peripheral blood. Bacterial DNA,
metabolites, or proteins circulating in the blood stream could,
in turn, modify BBB permeability (Braniste et al., 2014; Myles,
2014; Kumar and Forster, 2017; Cerovic et al., 2019; Parker et al.,
2019; Wang et al., 2019). Existing reports indicated bacterial DNA
in human blood with a possibility for brain access (Lelouvier
et al., 2016; Païssé et al., 2016; Schierwagen et al., 2018). Brain
entry of P. gingivalis, a bacterium associated with periodontal
disease, has been described (Dominy et al., 2019). Gingipain
inhibitors reduced the bacterial load and the bacteria-induced
neuro-inflammation in a mouse model (Dominy et al., 2019).
Among Spirochetes, Borrelia burgdorferi is a strain associated
with Lyme dementia that could enter the brain. In humans, this
specific strain can form biofilms similar to senile plaques. Aβ and
bacterial DNA appear as important constituents of these biofilms,
suggesting that amyloid plaques may originate in association with
or from the spirochetal colonies (Allen, 2016; Miklossy, 2016).
These examples highlight the need of tightly regulated
intestinal and brain barriers (Rahman et al., 2018). In AD, a
dysbiotic GM may enhance gut permeability and alter BBB
integrity, allowing the access of infectious agents or associated
molecules into the brain (Martin et al., 2018). Significantly,
intestinal and brain barriers are reactive to analogous pro-
inflammatory triggers. Circulating inflammatory cytokines IL-17,
interferon-gamma (IFN-γ), and the small intestine epithelium
protein zonulin can damage the intestinal–epithelia and BBBs
(Rahman et al., 2018).
GUT MICROBIOTA AND
AUTOANTIBODIES: INITIAL CLUES
Hypotheses linking modifications of the GM and production of
autoantibodies are emerging (Petta et al., 2018). Some evidence
supports the concept that specific dietary components may
affect B-cell maturation and activity, ultimately leading
to the formation of autoantibodies (Petta et al., 2018).
Obesity was associated with a systemic pro-inflammatory
state, characterized by changes in the frequency of B-cell

















TABLE 1 | Autoantibodies reported in neurodegenerative disease and post-TBI.
Autoantibodies Neuro-
pathology
Stage Model investigated Sample Observed effects Isotype References
Anti-neuronal
antibody
TBI Moderate acute TBI AM Serum – IgG Rudehill et al., 2006
Anti-neurofilament AD Moderate forms of AD H Serum, CSF – IgG. IgM Bartos et al., 2012
Anti-Aβ AD Mild to severe forms of
AD, early and late onset





IgG {IgG2}, Nab Myagkova et al., 2001; Bell et al., 2010; Daneman
et al., 2010; Schwartz and Shechter, 2010; Armulik
et al., 2017; Kisler et al., 2017; Rustenhoven et al.,
2017; Sommer et al., 2017; Montagne et al., 2018;
Nikolakopoulou et al., 2019
Anti-Tau AD, TBI Mid to severe forms of
AD
H Serum, CSF, tissue Levels correlated
with reduced
Plaque burden
IgG, Nab Du et al., 2001; Weksler et al., 2002; Mruthinti
et al., 2004; Brettschneider et al., 2005;
Rosenmann et al., 2006; Gruden et al., 2007;
Gustaw et al., 2008; Britschgi et al., 2009; Wilson
et al., 2009; Maftei et al., 2013; Qu et al., 2014
Anti-AMPA receptor AD, TBI Moderate to severe AD
Mild and repetitive
concussion in children
H Serum Levels increased in
moderate and
severe dementia
– Goryunova et al., 2007
Anti-NMDA
receptor
AD, TBI Moderate to severe AD






IgG Goryunova et al., 2007; Busse et al., 2014
Anti-acetyl choline
receptor
TBI TBI to different severity
in children
H Serum Levels correlate
with trauma severity
– Sorokina et al., 2011
Anti-Dopamine AD Mid to severe forms of
AD
H Serum Match to moderate
to severe dementia
progression
IgG Myagkova et al., 2001; Gruden et al., 2007
Anti-5-HT AD Mild to severe forms of
AD
H Serum Levels increased
during mild
dementia
– Myagkova et al., 2001
Anti-GFAP AD, TBI Pre-senile and senile














































TABLE 1 | Continued
Autoantibodies Neuro-
pathology
Stage Species model investigated Sample Observed effects Isotype References












IgG Mecocci et al., 1995; Gruden et al., 2007; Marchi
et al., 2013
Anti-microglia AD Mid to severe forms of
AD
H CSF – IgG McRae et al., 2007




H Serum, CSF Levels correlate
with erythrocytes
and proteins in CSF
IgG McIntyre et al., 2007; McIntyre et al., 2015
Anti-ceramide AD Chronic pathology in
TG mice
AM Serum Levels correlate
with plaque
formation
IgG Dinkins et al., 2015
Anti-RAGE AD Mild cognitive
impairment to severe
AD





IgG Mruthinti et al., 2004; Wilson et al., 2009
Anti-ATP synthase AD Mild to severe AD H Serum Induced the
inhibition of ATP
synthesis
IgG Vacirca et al., 2012


















IgG Karczewski et al., 2012
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TABLE 2 | Available molecules exerting BBB repairing and anti-inflammatory effects.
Category Mechanism(s) of
action
Reported effects In vivo /in vitro
models
Clinical trials References






Kucuk et al., 2002;
Kaya et al., 2003;
Hong et al., 2019
































Mice NA Senatorov et al.,
2019














2008; Zhong et al.,
2009; Wang et al.,
2016; Sinha et al.,
2018; Lazic et al.,
2019; Lyden et al.,
2019





In vivo NA Arango-Lievano
et al., 2018
Imatinib Kinase inhibitor Inhibition of PDGFR
signaling





Su et al., 2015;
Klement et al.,
2019








In vitro BBB model Inflammatory
conditions
Hue et al., 2015;













In vitro BBB model,
Anxa−/− mice
NA Cristante et al.,
2013; Purvis et al.,









Mice NA Religa et al., 2013




Rats NA Gong et al., 2019














In vitro BBB model NA Hind et al., 2016
subpopulation [e.g., reduction of the anti-inflammatory
IL-10+ regulatory B cell (Nishimura et al., 2013)] and by
an increase in autoantibody levels (Kosaraju et al., 2017).
Diets rich in polyunsaturated fatty acid are associated
with the suppression of pro-inflammatory responses and a
reduction of circulating autoantibodies (Pestka et al., 2014;
Tomasdottir et al., 2014). Dietary components impact the
composition of the gastrointestinal bacterial populations:
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consumption of prebiotics increases the intestinal levels
of Bifidobacterium and Lactobacillus (Singh et al., 2017),
with a possible link to B-cell differentiation, maturation,
and activation (Ouwehand et al., 2002). Diet can impact
autoantibody production, directly by promoting pro-
inflammatory conditions and indirectly by altering the GM.
In experimental autoimmune encephalomyelitis (EAE) it was
demonstrated that the commensal microbiota composition
is a pivotal factor for disease development (Lee et al.,
2011) and that modifying the GM impacts the levels of
T and B cells or the levels of circulating autoantibodies
(Ochoa-Repáraz et al., 2009, 2010).
BBB REPAIRING PHARMACOLOGY:
AVAILABLE OPTIONS
The multi-level implication of BBB damage in neurodegenerative
disorders has prompted the quest for pharmacological repairing
strategies, either directed at the endothelium or by indirect
targeting of the cellular players of peripheral and neuro-
inflammation. Currently tested drugs are either repurposed or
new (Table 2). Examples include losartan, an anti-hypertensive
molecule acting as an angiotensin II antagonist. Losartan
was shown to reduce BBB permeability in a rat model of
hypertension (Kucuk et al., 2002; Kaya et al., 2003) and
following pilocarpine-induced status epilepticus (Hong et al.,
2019). BBB protection by losartan depends on angiotensin
receptor type 1 (AT1) blockade. Another drug is rapamycin,
a specific inhibitor of the mammalian target of rapamycin
(mTOR) pathway. Rapamycin improved cerebrovascular and
cognitive function in a mouse model of AD (Van Skike et al.,
2018). Inhibition of mTOR preserved BBB integrity through
the upregulation of tight junction proteins and downregulation
of matrix metalloproteinase-9. A third option is anakinra,
which is the recombinant form of the human IL-1 receptor
antagonist (IL1-Ra) that inhibits IL-1α and IL-1β binding to
the IL-1 receptor type 1. As inflammation comprises BBB
dysfunction, the inhibition of IL-1 as proposed is a strategy
enabling cerebrovascular protection (Marchi et al., 2009, 2011;
Vezzani et al., 2011; Kenney-Jung et al., 2016). Recent strategies
include the development of IL-1Ra molecules fused with a
cell-penetrating peptide to enhance brain access (Zhang et al.,
2017). After transient middle cerebral artery occlusion in rats,
IL-1Ra-PEP reduced neuro-inflammation and ischemia (Zhang
et al., 2017). The fourth option is IPW-5371, a small molecule
blocking the transforming growth factor β receptor (TGFβR)
signaling. In a recent study (Senatorov et al., 2019), IPW
reduced hyperexcitability in a mouse model, protecting BBB
functions. The activated protein C (APC) therapeutic analog
3K3A-APC is a fifth option. This compound has BBB and
neuro-protective properties (Thiyagarajan et al., 2008; Zhong
et al., 2009; Wang et al., 2016; Sinha et al., 2018; Lazic et al.,
2019; Lyden et al., 2019) and it is in clinical trial for stroke
treatment (Lyden et al., 2019). Next is platelet-derived growth
factor subunits BB (PDGF-BB). Following an acute vascular
insult, activation of the PDGF receptor beta (PDGFRβ) by
PDGF-BB is beneficial, protecting the endothelium–pericyte
structures. The latter was reported in mouse models of status
epilepticus (Arango-Lievano et al., 2018) and cerebral ischemia
(Marushima et al., 2019). Conversely, in chronic disease settings
(e.g., AD, epilepsy, etc.), activation of PDGFRβ may participate
to inflammation (Rustenhoven et al., 2017; Klement et al., 2019).
Under this circumstance, blocking PDGFRβ signaling by using
the tyrosine kinase inhibitor Imatinib could represent an anti-
inflammatory strategy (Rustenhoven et al., 2017; Klement et al.,
2019). In general, reducing PDGFRβ signaling could lead to
contrasting effects, e.g., pericyte deficiency and BBB breakdown
(Bell et al., 2010; Daneman et al., 2010; Armulik et al., 2017;
Kisler et al., 2017; Montagne et al., 2018; Nikolakopoulou
et al., 2019) or anti-inflammatory (Rustenhoven et al., 2017;
Klement et al., 2019), depending on disease stage (acute vs.
chronic). Another option, Dexamethasone, is a glucocorticoid
effective in the formation and maintenance of endothelial tight
junctions (Hue et al., 2015; Na et al., 2017). Dexamethasone
was proposed to decrease the expression of the Jumonji Domain
Containing 3 gene (JMJD3) and metallo-proteinases (MMP-2,
MMP-3, and MMP-9). Finally, there is the vascular endothelial
growth factor (VEGF). Amyloid accumulation is associated with
endothelial apoptosis (Religa et al., 2013) in Alzheimer’s patients
as well as in mouse models. In AD mice, VEGF administration
rescued memory deficits by preventing Aβ-induced vascular
apoptosis (Religa et al., 2013). See Table 2 for complete drug
listing, mechanisms and bibliography.
PERSPECTIVES AND CHALLENGES
The importance of cerebrovascular dysfunction in
neurodegenerative disorders is twofold: BBB damage is
pathophysiological and it allows a diagnostic window, the latter
by exploiting specific proteins that shed from the damaged or
vascular wall cells to appear into accessible fluids, e.g., blood
or CSF. For instance, by dosing soluble PDGFRβ in CSF and
by using dynamic contrast-enhanced magnetic resonance
imaging, a recent study demonstrated BBB breakdown as an
early biomarker of human cognitive dysfunction (Montagne
et al., 2015; Nation et al., 2019).
Tackling the complex neurodegenerative puzzle requires
a continuous sharpening of pharmacological tools. This is
important because no efficacious disease-modifying strategy is
available to meaningfully delay or prevent disease progression.
The problematics here presented may stem from semantic habits
as the term neuro- indicates, for most, neurons only. Revisiting
nomenclature(s) may benefit, if not legitimize, holistic, and
neurovascular approaches to CNS disorders since it is evident
that considering neuronal circuits insulated from the influence
of glio-vascular cells is excessively reductionist.
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